AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S.
北芝加哥,伊利諾伊州和上海,2025年1月13日 /美通社/ -- 艾伯維公司(紐交所:ABBV)與信誠在明,信誠藥品集團有限公司的子公司(香港交易所:2096)今天宣佈了一項許可協議的選擇權,以開發SIM0500,這是一種在研的新藥候選物。目前,SIM0500正在中國和美國進行復發或難治性多發性骨髓瘤(MM)患者的1期臨牀試驗。
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3, developed independently by Simcere Zaiming using their T-cell engager polyspecific antibody technology platform. This molecule features a low affinity/high target-activating CD3 engaging arm and binding sites for the two tumor antigens: G-Protein-coupled receptor class 5 member D (GPRC5D) and B-cell maturation antigen (BCMA). SIM0500 has shown strong T cell cytotoxicity against multiple myeloma (MM) cells by leveraging a combination of various antitumor effects.
SIM0500是一種人源化的三特異性抗體,靶向GPRC5D、BCMA和CD3,由心切獨立開發,使用他們的T細胞接合多特異性抗體科技平台。該分子具有低親和力/高靶向激活的CD3接合臂和用於兩種腫瘤抗原的結合位點:G-蛋白偶聯受體5類成員D(GPRC5D)和B細胞成熟抗原(BCMA)。SIM0500通過利用各種抗腫瘤效應的組合,顯示出了對多發性骨髓瘤(MM)細胞的強T細胞細胞毒性。
"As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma"
"作爲血液惡性腫瘤的領導者,艾伯維致力於通過我們不懈的研發努力和合作,推動複雜癌症(如多發性骨髓瘤)的創新治療,"艾伯維血液學治療領域副總裁,醫學博士Mariana Cota Stirner說。"我們期待與心切合作,推動這一新型三特異性抗體的發展,這有助於解決多發性骨髓瘤患者尚未滿足的重大醫療需求。"
"SIM0500 is developed via Simcere Zaiming's proprietary T-cell engager platform," said Renhong Tang, PhD, CEO of Simcere Zaiming. "We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500. "
"SIM0500是通過心切獨有的T細胞接合平台開發的,"心切CEO唐仁宏博士說。"我們很高興與艾伯維合作這一新藥候選,期待共同推動SIM0500的臨牀開發。"
Simcere Zaiming will receive an upfront payment from AbbVie and is eligible to receive option fees and milestone payments of up to $1.055B, as well as tiered royalties on net sales outside of the Greater China territory. AbbVie is eligible to receive tiered royalties on net sales in the Greater China territory.
信誠在明將從艾伯維公司獲得預付款,並有資格獲得高達10.55億的選擇權費用和里程碑付款,以及在大中華地區以外的淨銷售額的分級特許權使用費。艾伯維公司有資格獲得在大中華地區淨銷售額的分級特許權使用費。
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and in situ CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
在艾伯維,我們致力於爲難治性癌症患者改變治療標準。我們正在推進一系列腫瘤類型的研究性治療藥物,包括血液腫瘤和實體腫瘤。我們致力於創建靶向治療腫瘤細胞繁殖或使其消除的靶向藥物。我們通過各種靶向治療模式來達成這一目標,包括抗體藥物偶聯物(ADCs)、免疫腫瘤學以及雙特異性和CAR-T平台。我們的專業團隊與創新合作伙伴聯手加速潛在的突破性治療藥物的推出。
在艾伯維公司,我們致力於改善難治性癌症患者的護理標準。我們正在推動一系列癌症類型的研究治療pipeline,包括血液癌症和實體腫瘤。我們的重點是創造針對性的藥物,這些藥物要麼阻礙癌細胞的繁殖,要麼促使其消除。我們通過各種靶向治療方式和生物干預實現這一目標,包括小分子藥物、抗體藥物偶聯物(ADCs)、免疫腫瘤治療藥物、多特異性抗體和原位CAR-t平台。我們專注和經驗豐富的團隊與創新合作伙伴攜手合作,加速潛在突破性藥物的交付。
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit .
今天,我們廣泛的腫瘤學產品組合包括已批准和正在研究的治療方案,涵蓋了多種血液腫瘤和實體瘤。我們正在評估20多種正在研究的藥物,並在一些世界上最普遍和最具破壞性的癌症中進行多項臨牀試驗。在努力對人們的生活產生顯著影響的過程中,我們致力於探索幫助患者獲得我們癌症藥物的解決方案。欲獲取更多信息,請訪問。
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. AbbVie strives to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in AbbVie's Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
關於艾伯維公司
艾伯維公司的使命是發現並提供創新藥物和解決方案,以解決當今嚴重的健康問題,並應對明天的醫療挑戰。艾伯維公司努力在多個關鍵治療領域產生卓越的影響——免疫學、腫瘤學、神經科學和眼科——以及艾伯維公司阿爾拉根醫美產品組合中的產品和服務。有關艾伯維公司的更多信息,請訪問我們的網站。請在LinkedIn、Facebook、Instagram、X(前身爲Twitter)和YouTube上關注@abbvie。
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA, Enweida, Endostar, and Enlituo. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.
關於Simcere Zaiming
Simcere Zaiming是一家專注於腫瘤學的生物製藥公司,是信立泰製藥集團有限公司(香港交易所:2096,"信立泰")的子公司。Simcere Zaiming成立於2023年,致力於開發突破性的治療方案,以滿足全球癌症患者未被滿足的臨牀需求。憑藉強大且創新的研發pipeline,擁有獨特的臨牀資產,Simcere Zaiming在中國成功推出了多款創新產品,包括COSELA、恩維達、恩多星和恩利托。該公司決心通過內部研發、製造和商業化能力,並與領先合作伙伴的戰略合作,向全球癌症患者提供可能具有變革性的治療選擇。
SOURCE AbbVie
消息來源 艾伯維
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因